Last edited by Kazishicage
Thursday, May 14, 2020 | History

2 edition of Para-aminosalicyclic acid and its sodium salt in treatment of pulmonary tuberculosis. found in the catalog.

Para-aminosalicyclic acid and its sodium salt in treatment of pulmonary tuberculosis.

James Brian Shaw

Para-aminosalicyclic acid and its sodium salt in treatment of pulmonary tuberculosis.

by James Brian Shaw

  • 304 Want to read
  • 37 Currently reading

Published .
Written in English


Edition Notes

Thesis (M.D.)--The Queen"s University of Belfast, 1951.

The Physical Object
Pagination1 v
ID Numbers
Open LibraryOL19927431M

Zheng J, et al. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. J Biol Chem. Aug 9;(32) [2]. Sy SK, et al. N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in drug-resistant pulmonary tuberculosis patients.   Antituberculosis agent; structural analog of aminobenzoic acid. a Uses for Aminosalicylic Acid Tuberculosis. Treatment of active (clinical) tuberculosis (TB) in conjunction with other antituberculosis agents. Designated an orphan drug by the US FDA for this use. Second-line agent used in treatment of drug-resistant TB caused by Mycobacterium tuberculosis .

The treatment of pulmonary tuberculosis has changed so radically in the past few years that we are now able to alleviate symptoms, save lives that were previously doomed, bring acute and far-advanced cases to surgery as a definitive form of therapy and even help to prevent operative and post-operative complications in a manner never before by: 2. Mechanism of Action. Bacteriostatic against Mycobacterium tuberculosis; inhibits onset of bacterial resistance to streptomycin and isoniazid. Mechanism of action postulated to be inhibition of folic acid synthesis (but without potentiation with antifolic compounds) and/or inhibition of synthesis of the cell wall component, mycobactin, thus reducing iron uptake by M. tuberculosis.

Suppliers, 15 Kerry, 13 Corel Pharma Chem, 10 Ideal Cures Pvt Ltd, 9 Sigachi Industries, 7 Roquette, 6 Seppic, 3 Microlex e.U, 3 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 BASF, 2 DFE Pharma, 2 The Dow Chemical Company, 2 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 2 Vasa Pharmachem, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Kima Chemical, 1 Aeon Procare. Synonym: 4,4′-Dihydroxyazobenzene-3,3′-dicarboxylic acid disodium salt, 5,5′-Azobis(salicylic acid, sodium salt), Mordant Yellow 5 Empirical Formula (Hill Notation): C 14 H .


Share this book
You might also like
Music in the Andes

Music in the Andes

Tracts of the British Anti-State-Church Association.

Tracts of the British Anti-State-Church Association.

The Last Book of Wonder

The Last Book of Wonder

Hamel

Hamel

Fleet registers

Fleet registers

For Our Pastor 7x9 Fruitwood Frame

For Our Pastor 7x9 Fruitwood Frame

The Escape of the plant that ate dirty socks

The Escape of the plant that ate dirty socks

Dr. Gangadhar Guru

Dr. Gangadhar Guru

The Second treasury of techniques for teaching adults.

The Second treasury of techniques for teaching adults.

The Problems of lasting peace revisited

The Problems of lasting peace revisited

Champions of cricket

Champions of cricket

Birds by night

Birds by night

Nicoll family and Islip grange

Nicoll family and Islip grange

Ground-water quality in the Cook Inlet Basin, Alaska, 1999

Ground-water quality in the Cook Inlet Basin, Alaska, 1999

Para-aminosalicyclic acid and its sodium salt in treatment of pulmonary tuberculosis by James Brian Shaw Download PDF EPUB FB2

The general principles of P.A.S. treatment in pulmonary tuberculosis are the same as with other chemotherapeutic agents and can be summed up as follows: except in the miliary forms of tuberculosis, chemotherapy should be used to achieve a definite goal ; this is not necessarily the [quot]cure[quot] of the disease, as shown by sputum con- version, radiological healing, [amp]:c., but is merely a point at Cited by: IT HAS been shown that para-aminosalicylic acid (PAS) has a definite bacteriostatic effect on human strains of Mycobacterium tuberculosis in vitro1 2 3 4 and in vivo Cited by: 5.

– Para-aminosalicylic acid (PAS): delayed-release granules, 4 g sachet (PASER® Jacobus) – Para-aminosalicylate sodium (sodium salt of PAS or PAS-sodium): • Powder for oral solution, g sachet (PAS-Na® Olainfarm) • 60% w/w delayed-release granules.

Of these derivatives, salicylic acid was found to be the most effective inhibitor; nevertheless, when a compound of various derivatives was prepared it was found to have a still more inhibiting effect than any of the other combinations, and to this new compound-paraaminoorthohydroxy benzoic acid-prepared by a Swedish chemist, the name Para-aminosalicylic acid was by: 6.

Para-Aminosalicylic Acid (P.A.S.) in Pulmonary Tuberculosis. and there appears to be little doubt that the new drug has established itself in the treatment of certain forms of tuberculosis.

The authors have given PAS as the sodium salt in solution by mouth. Best results have been attained by giving 20 to 30 gm. a day and by obtaining blood Cited by: For the treatment of tuberculosis aminosalicylic acid is administered orally (as a free acid or as sodium, potassium or calcium salts) or parenterally (as sodi-um aminosalicylate).

More recently different dosage forms for pulmonary delivery have been described, as. Para-aminosalicylic acid (INN aminosalicylic acid; PAS) is a bacteriostatic chemotherapeutic agent used in the therapy of all forms of tuberculosis, both pulmonary and extrapulmonary, caused by.

Wilson J, et al. () Para-aminosalicylic acid (PAS) desensitization review in a case of multidrug-resistant pulmonary tuberculosis. Int J Tuberc Lung Dis 7, 7. ethambutol (ETH) in the early s. 6 It is bacteristatic but may help to slow development of resistance to other drugs, especially INH and streptomycin (STR) [DrugBank].

Para-aminosalicylic acid (PAS) is one of antimycobacterial drugs currently used for multidrug resistant tuberculosis. Although it has been in clinical use for over 60 years its mechanism(s) of action remains elusive. Here we report that PAS is a prodrug targeting dihydrofolate reductase (DHFR) through an unusual and novel mechanism of action.

4-Aminosalicylic acid, also known as para-aminosalicylic acid (PAS) and sold under the brand name Paser among others, is an antibiotic primarily used to treat tuberculosis. Specifically it is used to treat active drug resistant tuberculosis together with other antituberculosis lism: liver. Aminosalicylic acid and its salts are second-line antimycobacterials given orally in the treatment of multidrug-resistant tuberculosis.

They should always be given with other antituberculous drugs. Aminosalicylic acid may be given as the acid or as the sodium salt. Sodium aminosalicylate g is equivalent to about 1 g of aminosalicylic acid. Abstract. Recent studies have shown that treatment of pulmonary tuberculosis with isoniazid plus p-aminosalicylic acid (PAS) at home is, in the majority of cases, as satisfactory as treatment with the same combination of drugs in sanatorium and does not appear to expose the patient's contacts to.

Para-aminosalicylic acid (PAS) is one of the last remaining drugs available to treat extensively drug-resistant (XDR) tuberculosis. Good outcomes (81% 5 year survival) were documented when PAS was first used with streptomycin, yet results of PAS with remaining potentially effective drugs for the treatment of XDR tuberculosis are poor (mortality 30–90%).Cited by:   Folate biosynthesis is an established anti-infective target, and the antifolate para-aminosalicylic acid (PAS) was one of the first anti-infectives introduced into clinical practice based on target-based drug discovery.

Fifty years later, PAS continues in use for by:   [the role of acetylation in the effectiveness of treatment with combined isoniazid and para-aminosalicylic acid, and isoniazid with para-aminobenzoic acid, in pulmonary tuberculosis.] vitolo a.

bull sci med (bologna),01 oct cited by: 0 articles | pmid: Author: Debray. Para-Aminosalicylic Acid in the Treatment of Pulmonary Tuberculosis* SAMUEL PHILLIPS, M.D., F.C.C.P., JOHN C. LARKIN, JR., M.D.

and WILLARD A. LITZENBERGER, M.D. Memphis, Tennessee This study was an attempt to determine whether the adminis­ tration of large doses of para-aminosalicylic acid, 18 to 24 grams.

PAS (Para-aminosalicylic acid or PASER); PAS-sodium (Para-aminosalicylic acid sodium) PAS was discovered in Initially, PAS was used to treat TB, but with the discovery of other more potent drugs including rifampicin, its use in first line regimens was discontinued.

US$; United States dollars. a The selected treatment was the longest and most expensive regimen for multidrug-resistant tuberculosis: 12 months of capreomycin, protionamide, cycloserine, moxifloxacin and para-aminosalicylic acid sodium salt, followed by 12 months of protionamide, cycloserine, moxifloxacin and para-aminosalicylic acid sodium salt.

b Cost of treatment from the same suppliers as. This is about 1 1/4 teaspoons of sodium chloride (salt). They further recommend that if you have heart failure, you reduce your sodium to 2, mg. Listings of the sodium content of various foods and other guidelines can be found on the AHA’s website.

1/4 teaspoon salt = mg sodium 1/2 teaspoon salt = 1, mg sodium. This application is for PAS -GR a gastro-resistant granule formulation of para -aminosalicylic acid intended for the treatment of tuberculosis (TB) in combination with other medicinal products.

The proposed indication for PAS -GR is the treatment of tuberculosis in combination with. This book is a companion handbook to existing WHO policy guidance on the management of multidrug-resistant tuberculosis, including the WHO guidelines for the programmatic management of drug-resistant tuberculosis, WHO interim policy guidance on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis, and the WHO interim policy guidance on the use of delamanid in the.Aminosalicylates are an effective antiinfective alone or in combined therapy and reduce serum cholesterol and triglycerides by lowering LDL and VLDL.

Uses. In combination with streptomycin or isoniazid or both in treatment of pulmonary and extrapulmonary tuberculosis to delay .para-aminosalicylic acid (p.a.s.) in pulmonary tuberculosis Previous Article SURGERY IN PARKINSON'S DISEASE DIVISION OF LATERAL PYRAMIDAL TRACT FOR TREMOR Next Article MEGALOBLASTIC ANÆMIA IN AN INFANTCited by: